APN:JSEAspen Pharmacare Holdings Limited Analysis
Data as of 2026-08-25 - not real-time
ZAC 14,878.00
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Aspen Pharmacare Holdings Limited is priced at ZAC 14,878.00, and its moving averages give no clean directional read — the structure is neutral. Over a rolling month the price has lost 1.5%. With RSI at 53.6 the momentum picture is neutral, alongside a bullish MACD signal. Price has been bracketed by support at ZAC 13,796.00 and resistance at ZAC 15,404.00.
Multiples put this in undervalued territory: 12.4 times earnings against the sector's 31.3. Consensus targets land 9.4% above where the shares trade now. Revenue is contracting at 4.3% on a -4.7% profit margin. The 1.43% dividend yield looks covered by current payout levels.
The composite risk read is 4/10, putting it in moderate territory. With 30-day volatility of 35.2%, a beta of 0.21 and a maximum drawdown of 15.7%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Timeframes disagree: the short-term read is buy while the long-term read is hold, conviction 3 out of 10.
Multiples put this in undervalued territory: 12.4 times earnings against the sector's 31.3. Consensus targets land 9.4% above where the shares trade now. Revenue is contracting at 4.3% on a -4.7% profit margin. The 1.43% dividend yield looks covered by current payout levels.
The composite risk read is 4/10, putting it in moderate territory. With 30-day volatility of 35.2%, a beta of 0.21 and a maximum drawdown of 15.7%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Timeframes disagree: the short-term read is buy while the long-term read is hold, conviction 3 out of 10.
Top Market Events
ad-hoc-news1monAspen stock holds as Aspen Pharmacare reports fiscal 2025 resultsAspen stock is anchored by fiscal 2025...
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 4/10
Key Factors
- Trading above the 200-day average of 12839.30
- MACD momentum is positive
- RSI at 53.6 is in neutral territory
Medium Term
1–3 yearsPositive
Model confidence: 4/10
Key Factors
- P/E of 12.4 versus sector average of 31.3
- Trading above the 200-day average of 12839.30
- Analyst targets imply +9.4% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- P/E of 12.4 versus sector average of 31.3
- Negative profit margin of -4.7%
- Analyst targets imply +9.4% versus the current price
Key Metrics & Analysis
Financial Health
Revenue Growth-4.30%
Profit Margin-4.69%
P/E Ratio12.4
ROE-2.17%
ROA2.85%
Debt/Equity40.63
P/B Ratio0.8
Op. Cash FlowZAC6.9B
Free Cash FlowZAC-17675999232
Industry P/E31.3
Technical Analysis
TrendNeutral
RSI53.6
SupportZAC 13,796.00
ResistanceZAC 15,404.00
MA 20ZAC 14,670.25
MA 50ZAC 14,954.88
MA 200ZAC 12,839.30
MACDBullish
VolumeIncreasing
Fear & Greed Index93.32
Valuation
Fair ValueZAC 7,735.84
Target PriceZAC 16,275.00
Upside/Downside9.39%
GradeUndervalued
TypeValue
Dividend Yield1.43%
Risk Assessment
Beta0.21
Volatility35.21%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskHigh
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.